
Nocturia Market Report and Forecast 2025-2034
Description
The nocturia market size was valued at USD 3.30 Billion in 2024, driven by the rising prevalence of nocturia across the 8 major markets. The market is expected to grow at a CAGR of 8.30% during the forecast period of 2025-2034, with the values likely to rise USD 7.32 Billion by 2034.
Nocturia Market Overview
Nocturia is a medical condition characterized by excessive urination at night, with the affected individual visiting the bathroom twice or more at nighttime. Patients with nocturia can suffer from sleep deprivation which can greatly impact the quality of life. It is also linked with obesity, depression, diabetes, and heart disease, among others.
The market is driven by the rising prevalence of nocturia, with over 50% of men and women aged 60 or more reported to be diagnosed with the condition. The incidence of nocturia in older men is higher than in older women, amounting to 50% in men between 70 to 79 years having two or more nightly voids. The growing number of patients with nocturia is expected to directly drive the nocturia market demand, with more and more individuals seeking effective treatment options to manage the symptoms.
As people age, they are more likely to experience nocturia, which also tends to become more severe. With the rising geriatric population, clinically significant nocturia cases are expected to surge. According to the United Nations Population Fund, the number of older people aged 60 years, or more is expected to reach 2.1 billion worldwide, accounting for 22% of the total population. Moreover, it is estimated that the elderly population in India will double, almost reaching 347 million in 2050. This indicates that the rapid growth of the geriatric population is likely to augment nocturia market share in the coming years._x000D__x000D_
The market is also supported by increased research initiatives aimed at finding innovative treatment solutions to treat nocturia. In April 2023, a randomized controlled trial revealed the potential of Erbium YAG laser treatment to manage overactive bladder, often accompanied by frequent urination and nocturia. The study showed positive results, with women receiving the intervention reporting less nocturia and urination urgency, along with additional benefits. The development of such novel treatment methods is anticipated to boost nocturia market growth.
Other factors that impact the market dynamics include the growing technological advancements in diagnostic tools and digital health applications for monitoring symptoms and treatment efficacy. Rising healthcare expenditure, and the introduction of advanced therapies also impact the market significantly. Moreover, the market is expected to witness increased demand owing to the high prevalence rate of chronic conditions such as obesity and hypertension that make an individual prone to nocturia.
Nocturia Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Advancements in Treatment Options
Technological advancements coupled with pharmaceutical progressions have led to the development of new and improved treatment options for nocturia. From behavioral interventions to pharmacotherapy and surgical procedures, the rising accessibility of these therapeutic interventions is fuelling the nocturia market share. Further, the market is witnessing a diversification of available treatments, which attracts a wider patient base, thereby driving market demand.
Integration of Digital Health Technologies
The integration of digital health technologies, such as mobile apps for bladder monitoring and telehealth services for remote consultations, is significantly impacting the market landscape. With the help of these digital tools, patient management along with adherence to treatment plans are likely to improve. This market trend follows a patient-centric approach by leveraging digital solutions, focusing on the convenience of the patients, and is expected to bolster nocturia market demand in the coming years.
Heightened Awareness and Diagnosis
The rising awareness among the public and healthcare professionals about nocturia as a treatable condition, rather than a normal part of aging, has accelerated diagnosis rates and encouraged treatment-seeking behaviour. Moreover, this trend also supports ongoing research and development aimed at finding effective therapeutics to treat nocturia, contributing to market growth and innovation in the healthcare sector.
Rising Healthcare Expenditure
One of the significant nocturia market trends is the increased healthcare expenditure that enables substantial investment in the diagnosis and treatment of nocturia. This is expected to accelerate the development of advanced therapies more accessible to a broader patient population. This financial investment also supports the adoption of innovative medical technologies, further driving market growth.
Nocturia Market Segmentation
Nocturia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Drug Type
Market Breakup by Dosage Form
Market Breakup by Distribution Channel
Market Breakup by Region
Nocturia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Key Queries Solved in the Nocturia Market Report
Nocturia Market Overview
Nocturia is a medical condition characterized by excessive urination at night, with the affected individual visiting the bathroom twice or more at nighttime. Patients with nocturia can suffer from sleep deprivation which can greatly impact the quality of life. It is also linked with obesity, depression, diabetes, and heart disease, among others.
The market is driven by the rising prevalence of nocturia, with over 50% of men and women aged 60 or more reported to be diagnosed with the condition. The incidence of nocturia in older men is higher than in older women, amounting to 50% in men between 70 to 79 years having two or more nightly voids. The growing number of patients with nocturia is expected to directly drive the nocturia market demand, with more and more individuals seeking effective treatment options to manage the symptoms.
As people age, they are more likely to experience nocturia, which also tends to become more severe. With the rising geriatric population, clinically significant nocturia cases are expected to surge. According to the United Nations Population Fund, the number of older people aged 60 years, or more is expected to reach 2.1 billion worldwide, accounting for 22% of the total population. Moreover, it is estimated that the elderly population in India will double, almost reaching 347 million in 2050. This indicates that the rapid growth of the geriatric population is likely to augment nocturia market share in the coming years._x000D__x000D_
The market is also supported by increased research initiatives aimed at finding innovative treatment solutions to treat nocturia. In April 2023, a randomized controlled trial revealed the potential of Erbium YAG laser treatment to manage overactive bladder, often accompanied by frequent urination and nocturia. The study showed positive results, with women receiving the intervention reporting less nocturia and urination urgency, along with additional benefits. The development of such novel treatment methods is anticipated to boost nocturia market growth.
Other factors that impact the market dynamics include the growing technological advancements in diagnostic tools and digital health applications for monitoring symptoms and treatment efficacy. Rising healthcare expenditure, and the introduction of advanced therapies also impact the market significantly. Moreover, the market is expected to witness increased demand owing to the high prevalence rate of chronic conditions such as obesity and hypertension that make an individual prone to nocturia.
Nocturia Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Advancements in Treatment Options
Technological advancements coupled with pharmaceutical progressions have led to the development of new and improved treatment options for nocturia. From behavioral interventions to pharmacotherapy and surgical procedures, the rising accessibility of these therapeutic interventions is fuelling the nocturia market share. Further, the market is witnessing a diversification of available treatments, which attracts a wider patient base, thereby driving market demand.
Integration of Digital Health Technologies
The integration of digital health technologies, such as mobile apps for bladder monitoring and telehealth services for remote consultations, is significantly impacting the market landscape. With the help of these digital tools, patient management along with adherence to treatment plans are likely to improve. This market trend follows a patient-centric approach by leveraging digital solutions, focusing on the convenience of the patients, and is expected to bolster nocturia market demand in the coming years.
Heightened Awareness and Diagnosis
The rising awareness among the public and healthcare professionals about nocturia as a treatable condition, rather than a normal part of aging, has accelerated diagnosis rates and encouraged treatment-seeking behaviour. Moreover, this trend also supports ongoing research and development aimed at finding effective therapeutics to treat nocturia, contributing to market growth and innovation in the healthcare sector.
Rising Healthcare Expenditure
One of the significant nocturia market trends is the increased healthcare expenditure that enables substantial investment in the diagnosis and treatment of nocturia. This is expected to accelerate the development of advanced therapies more accessible to a broader patient population. This financial investment also supports the adoption of innovative medical technologies, further driving market growth.
Nocturia Market Segmentation
Nocturia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Polyuria
- Nocturnal Polyuria
- Low Nocturnal Bladder Capacity
- Mixed Nocturia
Market Breakup by Drug Type
- Anti-cholinergic
- Desmopressin
- Antibiotic
- Anti-spasmodic
- Others
Market Breakup by Dosage Form
- Tablet
- Nasal Spray
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Drug Store
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Nocturia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Urigen Pharmaceuticals
- Glenmark Pharmaceuticals
- AbbVie Inc.
- Teva Pharmaceuticals
- Avadel Pharmaceuticals
- Astellas Pharma
- Dainippon Sumitomo Pharma
- Feering Pharmaceuticals
- AA Pharma Inc.
- Pfizer Inc
Key Queries Solved in the Nocturia Market Report
- How has the market performed so far and how will it perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of nocturia affect the market landscape?
- How does the rise in the geriatric population impact the nocturia market size?
- What disease type will dominate the market share?
- Which dosage form is expected to have a high market value in the coming years?
- Which drug type will experience the highest demand in the market segment?
- Which distribution channel will significantly impact market growth?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in nocturia treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Nocturia Market Overview – 8 Major Markets
- 3.1 Nocturia Market Historical Value (2018-2024)
- 3.2 Nocturia Market Forecast Value (2025-2034)
- 4 Nocturia Overview
- 4.1 Guidelines and Stages
- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
- 5.1 Patient Profile Overview
- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Nocturia Epidemiology Scenario and Forecast – 8 Major Markets
- 6.1 8MM Epidemiology Scenario Overview (2018-2034)
- 6.2 United States Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3 EU-4 and United Kingdom Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3.1 Germany Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3.2 France Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3.3 Italy Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3.4 Spain Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.3.5 United Kingdom Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.4 Japan Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 6.5 India Nocturia Epidemiology Scenario and Forecast (2018-2034)
- 7 Nocturia Market Landscape – 8 Major Markets
- 7.1 Nocturia: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Nocturia: Product Landscape
- 7.2.1 Analysis by Disease Type
- 7.2.2 Analysis by Drug Type
- 7.2.3 Analysis by Dosage Forms
- 8 Nocturia Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Nocturia Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Nocturia Market Segmentation (218-2034) - 8 Major Markets
- 11.1 Nocturia Market (2018-2034) by Disease Type
- 11.1.1 Market Overview
- 11.1.2 Polyuria
- 11.1.3 Nocturnal Polyuria
- 11.1.4 Low Nocturnal Bladder Capacity
- 11.1.5 Mixed Nocturia
- 11.2 Nocturia Market (2018-2034) by Drug Type
- 11.2.1 Market Overview
- 11.2.2 Anti-cholinergic
- 11.2.3 Desmopressin
- 11.2.4 Antibiotic
- 11.2.5 Anti-spasmodic
- 11.2.6 Others
- 11.3 Nocturia Market (2018-2034) by Dosage Form
- 11.3.1 Market Overview
- 11.3.2 Tablet
- 11.3.3 Nasal Spray
- 11.4 Nocturia Market (2018-2034) by Distribution Channel
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacies
- 11.4.3 Drug Store
- 11.4.4 Retail Pharmacies
- 11.4.5 Online Pharmacies
- 11.5 Nocturia Market (2018-2034) by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan
- 11.5.5 India
- 12 United States Nocturia Market (218-2034)
- 12.1 United States Nocturia Market Historical Value (2018-2024)
- 12.2 United States Nocturia Market Forecast Value (2025-2034)
- 12.3 United States Nocturia Market (2018-2034) by Disease Type
- 12.3.1 Market Overview
- 12.3.2 Polyuria
- 12.3.3 Nocturnal Polyuria
- 12.3.4 Low Nocturnal Bladder Capacity
- 12.3.5 Mixed Nocturia
- 12.4 United States Nocturia Market (2018-2034) by Drug Type
- 12.4.1 Market Overview
- 12.4.2 Anti-cholinergic
- 12.4.3 Desmopressin
- 12.4.4 Antibiotic
- 12.4.5 Anti-spasmodic
- 12.4.6 Others
- 13 EU-4 and United Kingdom Nocturia Market (218-2034)
- 13.1 EU-4 and United Kingdom Nocturia Market Historical Value (2018-2024)
- 13.2 EU-4 and United Kingdom Nocturia Market Forecast Value (2025-2034)
- 13.3 EU-4 and United Kingdom Nocturia Market Overview
- 13.4 EU-4 and United Kingdom Nocturia Market (2018-2034) by Disease Type
- 13.4.1 Market Overview
- 13.4.2 Polyuria
- 13.4.3 Nocturnal Polyuria
- 13.4.4 Low Nocturnal Bladder Capacity
- 13.4.5 Mixed Nocturia
- 13.5 EU-4 and United Kingdom Nocturia Market (2018-2034) by Drug Type
- 13.5.1 Market Overview
- 13.5.2 Anti-cholinergic
- 13.5.3 Desmopressin
- 13.5.4 Antibiotic
- 13.5.5 Anti-spasmodic
- 13.5.6 Others
- 14 Japan Nocturia Market
- 14.1 Japan Nocturia Market Historical Value (2018-2024)
- 14.2 Japan Nocturia Market Forecast Value (2025-2034)
- 14.3 Japan Nocturia Market (2018-2034) by Disease Type
- 14.3.1 Market Overview
- 14.3.2 Polyuria
- 14.3.3 Nocturnal Polyuria
- 14.3.4 Low Nocturnal Bladder Capacity
- 14.3.5 Mixed Nocturia
- 14.4 Japan Nocturia Market (2018-2034) by Drug Type
- 14.4.1 Market Overview
- 14.4.2 Anti-cholinergic
- 14.4.3 Desmopressin
- 14.4.4 Antibiotic
- 14.4.5 Anti-spasmodic
- 14.4.6 Others
- 15 India Nocturia Market
- 15.1 India Nocturia Market (2018-2034) Historical Value (2018-2024)
- 15.2 India Nocturia Market (2018-2034) Forecast Value (2025-2034)
- 15.3 India Nocturia Market (2018-2034) by Disease Type
- 15.3.1 Market Overview
- 15.3.2 Polyuria
- 15.3.3 Nocturnal Polyuria
- 15.3.4 Low Nocturnal Bladder Capacity
- 15.3.5 Mixed Nocturia
- 15.4 India Nocturia Market (2018-2034) by Drug Type
- 15.4.1 Market Overview
- 15.4.2 Anti-cholinergic
- 15.4.3 Desmopressin
- 15.4.4 Antibiotic
- 15.4.5 Anti-spasmodic
- 15.4.6 Others
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 Japan PMDA
- 16.1.4 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication Year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by Year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Urigen Pharmaceuticals
- 22.1.1 Financial Analysis
- 22.1.2 Product Portfolio
- 22.1.3 Demographic Reach and Achievements
- 22.1.4 Mergers and Acquisitions
- 22.1.5 Certifications
- 22.2 Glenmark Pharmaceuticals
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 AbbVie Inc.
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 Teva Pharmaceuticals
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 Avadel Pharmaceuticals
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 Astellas Pharma
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 Dainippon Sumitomo Pharma
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 Feering Pharmaceuticals
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 AA Pharma Inc.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 Pfizer Inc.
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 23 Nocturia Treatment Drugs - Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Company Competitiveness Analysis (Additional Insight)
- 25.1 Very Small Companies
- 25.2 Small Companies
- 25.3 Mid-Sized Companies
- 25.4 Large Companies
- 25.5 Very Large Companies
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.